For 5-amino-1MQ specifically: Preclinical studies have not prominently described heart rate elevation as a dominant signal The mechanism (NNMT inhibition, NAD+ preservation) does not have the same direct cardiac implications as nuclear receptor agonism Human cardiovascular data at clinically relevant exposures are limited For physicians, the current evidence base does not support a major cardiovascular safety flag, but the limited human dataset means confident statements are premature
AOD-9604, a synthetic fragment derived from the C-terminal region of human growth hormone, has been subjected to extensive clinical evaluation involving over 900 participants across six randomized controlled trials
Contact La Belle Vie Clinic to schedule your evaluation and take a confident, evidence-based step toward better health
And heres where it gets more interesting NNMT is hyperactive in conditions like obesity & type 2 diabetes, Alzheimers & Parkinsons disease, aging in general
Some research-model literature has examined combined administration of BPC-157 and TB-500 in tissue-repair contexts
They range from mild to debilitating and life-threatening